-
Featured
Propensity Score Weighting Accounts Well for Placebo Response in Two Trials of Medical Therapy for MDD
Maurizio Fava, MD, and colleagues previously developed an AI approach to account for the propensity to respond to placebo in randomized, controlled trials of drugs for major depressive disorder (MDD), and they show the method more accurately interprets the results of trials complicated by the placebo response.
-
Featured
Multiple Intra-articular Steroid Hip Injections Bring Greater Infection Risk
Multiple intra-articular steroid hip injections versus one injection bring far greater risk of periprosthetic joint infections for total hip arthroplasty patients.
-
Digital App Improves Quality of Life for Caregivers of Patients Undergoing HSCT
A digital app created by Jamie M. Jacobs, PhD, Areej El-Jawahri, MD, and colleagues significantly improved quality of life, depression and PTSD symptoms, and coping skills of family and friend caregivers of patients undergoing hematopoietic stem cell transplantation, compared with usual care.
-
Artifactual Bias in Large MRI Analyses of Brain Development Is Pervasive, Requires Multipronged Intervention
Joshua L. Roffman, MD, and colleagues demonstrated that in large pediatric brain MRI cohorts, inadequate quality control of scans undermines the advantages of large sample size to detect true findings. However, biases related to poor quality images can be successfully addressed through automated and manual interventions.
-
Review: Cardiovascular Effects and Safety of Classic Psychedelics
Jeremy N. Ruskin, MD, and colleagues recently reviewed how classic psychedelics affect the cardiovascular system. They share an overview of the current state of the evidence and the knowledge gaps that require further investigation.
-
Academic Medical Centers Department of Psychiatry Chair, Maurizio Fava, MD, Discusses U.S. News & World Report Ranking Mass General #1 for Psychiatry
The Massachusetts General Hospital Department of Psychiatry has been recognized for its exceptional commitment to advancing mental health care. Mass General was ranked #1 in the nation for Psychiatry in 2025-26 by U.S. News and World Report.
Psychiatry Contributors
-
David Mischoulon, MD, PhD
Director, Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Joyce R. Tedlow Professor of Psychiatry, Harvard Medical School
Recent Article
Heated Yoga Linked to Reduction of Moderate to Severe Depressive Symptoms in Randomized Controlled Trial
-
Eve Valera, PhD
Researcher, Athinoula A. Martinos Center for Biomedical Imaging
Recent Article
Q&A: Dr. Eve Valera on Intimate Partner Violence and Brain Injury
-
Jodi Gilman, PhD
Director of Neuroscience, Center for Addiction Medicine, Massachusetts General Hospital
Recent Article
Pain Catastrophizing Is Associated With Reduced Neural Response to Monetary Reward
-
Jordan W. Smoller, MD, ScD
Associate Chief for Research, Department of Psychiatry, Massachusetts General Hospital, Director, Psychiatric and Neurodevelopmental Genetics Unit, Professor of Psychiatry at Harvard Medical School and Professor in the Department of Epidemiology at the Harvard School of Public Health
Recent Article
Psychiatric Disorders Not Associated With Incidental Findings in Medically Actionable Genes
-
Maurizio Fava, MD
Psychiatrist-In-Chief; Director, Division of Clinical Research of the MGH Research Institute, Executive Director, Clinical Trials Network and Institute (CTNI), Massachusetts General Hospital, Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.